Thomas Steyer Farallon Capital Management
Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
EA
Electronic Arts
EA
|
+$492M |
| 2 |
Broadcom
AVGO
|
+$292M |
| 3 |
KKR & Co
KKR
|
+$280M |
| 4 |
Roivant Sciences
ROIV
|
+$248M |
| 5 |
Mastercard
MA
|
+$138M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
EXAS
Exact Sciences
EXAS
|
+$650M |
| 2 |
CYBR
CyberArk
CYBR
|
+$470M |
| 3 |
Salesforce
CRM
|
+$334M |
| 4 |
Nasdaq
NDAQ
|
+$290M |
| 5 |
RNAM
Avidity Biosciences
RNAM
|
+$233M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.53% |
| 2 | Communication Services | 11.31% |
| 3 | Financials | 11.23% |
| 4 | Technology | 10.28% |
| 5 | Consumer Discretionary | 4.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EA
1
DELISTED
Electronic Arts
EA
| $1.52B | 7.99% |
7,470,000
+2,435,000
| +48% | +$492M |
|
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$809B
| $1.5B | 7.85% |
2,300,000
-700,000
| -23% | -$476M |
|
3
Revolution Medicines
RVMD
$44.9B
| $1.32B | 6.94% |
13,604,796
-978,000
| -7% | -$98.8M |
|
4
Amazon
AMZN
$2.79T
| $879M | 4.61% |
4,218,394
-281,500
| -6% | -$62M |
|
5
Microsoft
MSFT
$3.59T
| $868M | 4.55% |
2,344,779
+130,700
| +6% | +$54.7M |
|
6
Aon
AON
$75.3B
| $811M | 4.25% |
2,512,638
-152,600
| -6% | -$50.7M |
|
7
BridgeBio Pharma
BBIO
$15.9B
| $695M | 3.65% |
9,365,463
+367,000
| +4% | +$26.6M |
|
8
PUT
Invesco Aerospace & Defense ETF
PPA
$8.25B
| $691M | 3.62% |
+3,600,000
| New | +$629M |
|
9
Protagonist Therapeutics
PTGX
$9.99B
| $669M | 3.51% |
6,348,906
+204,900
| +3% | +$18.1M |
|
10
Natera
NTRA
$47.9B
| $641M | 3.36% |
3,207,366
-707,000
| -18% | -$152M |
|
11
Exelixis
EXEL
$13.4B
| $562M | 2.95% |
13,111,010
-2,598,490
| -17% | -$112M |
|
|
12
Broadcom
AVGO
$1.75T
| $551M | 2.89% |
1,779,500
+887,100
| +99% | +$292M |
|
13
UnitedHealth
UNH
$350B
| $493M | 2.59% |
1,821,706
+222,800
| +14% | +$66.4M |
|
14
Synopsys
SNPS
$76.2B
| $481M | 2.52% |
1,213,300
+214,100
| +21% | +$96.8M |
|
15
Boston Scientific
BSX
$73B
| $469M | 2.46% |
7,470,684
+31,120
| +0.4% | +$2.49M |
|
16
Thermo Fisher Scientific
TMO
$233B
| $433M | 2.27% |
881,485
+245,800
| +39% | +$133M |
|
|
17
KKR & Co
KKR
$97.4B
| $432M | 2.27% |
4,671,800
+2,654,100
| +132% | +$280M |
|
18
Lantheus
LNTH
$6.53B
| $424M | 2.22% |
5,583,479
+156,000
| +3% | +$11.2M |
|
19
Wabtec
WAB
$50.3B
| $402M | 2.11% |
1,609,403
-866,600
| -35% | -$210M |
|
|
SCHW
20
Charles Schwab
SCHW
$194B
| $372M | 1.95% |
3,955,657
+616,000
| +18% | +$60.4M |
|
21
Liquidia Corp
LQDA
$6.14B
| $327M | 1.71% |
8,656,038
| – | – |
|
22
Crinetics Pharmaceuticals
CRNX
$8.99B
| $303M | 1.59% |
8,338,098
+1,405,000
| +20% | +$62.8M |
|
23
Alphabet (Google) Class C
GOOG
$4.18T
| $286M | 1.5% |
996,231
+209,191
| +27% | +$65.7M |
|
|
24
Roivant Sciences
ROIV
$26.2B
| $268M | 1.41% |
9,675,000
+9,638,000
| +26,049% | +$248M |
|
25
Visa
V
$693B
| $254M | 1.33% |
840,710
+144,800
| +21% | +$46.6M |
|
Similar funds
Thomas Steyer's Q1 2026 Portfolio in Review
As of Q1 2026, Thomas Steyer held 204 positions worth $19.1B, down 17% from $23.1B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Thomas Steyer withdrew a net $3.24B in Q1 2026, closing 31 positions and reducing 30 holdings. Its most notable exit was Exact Sciences, an estimated $650M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 41% a quarter earlier, followed by Communication Services and Financials.
Against the trend, Thomas Steyer opened a new position in Dianthus Therapeutics worth $70.2M.
- Thomas Steyer's largest Q1 2026 buy was Dianthus Therapeutics: 836,000 shares worth $70.2M.
- Thomas Steyer added most to Electronic Arts in Q1 2026, an estimated $492M increase.
- Thomas Steyer's biggest Q1 2026 reduction was Wabtec, cutting an estimated $210M.
- Thomas Steyer fully exited Exact Sciences in Q1 2026, selling an estimated $650M.
- Thomas Steyer's ten largest holdings make up 50% of its $19.1B portfolio in Q1 2026.
- Thomas Steyer opened 48 new positions and closed 31 in Q1 2026.
- Thomas Steyer's portfolio value fell 17% quarter-over-quarter to $19.1B.
Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.